Cargando…
Redefining the role of thiazolidinediones in the management of type 2 diabetes
There is a need to evaluate oral glucose-lowering agents not only for their value in achieving glycemic control but also for their impact on cardiac risk factor modification. This article reviews the evidence base for the two thiazolinediones currently available, pioglitazone and rosiglitazone. Thes...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672454/ https://www.ncbi.nlm.nih.gov/pubmed/19436665 |